Response to Comment on D'Addio et al. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes 2022;71:1800-1806

Diabetes. 2022 Sep 1;71(9):e14. doi: 10.2337/dbi22-0020.

Authors

Francesca D'Addio^{1

2}, Paolo Fiorina^{1

2

3}

Affiliations

¹ International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Università di Milano, Milan, Italy.
² Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
³ Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA.

PMID: 35984961
DOI: 10.2337/dbi22-0020

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter
Comment

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Diabetes Mellitus, Type 1* / genetics
Humans
SARS-CoV-2
Vaccines, Synthetic
mRNA Vaccines / adverse effects

Substances

COVID-19 Vaccines
Vaccines, Synthetic
mRNA Vaccines